Cogent Biosciences' Lead Cancer Drug Cuts Disease Progression Or Death Risk By 50% In Stomach Cancer Trial

Core Insights - Cogent Biosciences, Inc. (NASDAQ:COGT) stock is experiencing significant upward movement, with a trading volume of 10.95 million shares compared to the average of 1.97 million shares [1] Group 1: Clinical Trial Results - The company has reported data from its Phase 3 PEAK trial, which tested the combination of bezuclastinib and Pfizer's Sutent in patients with imatinib-resistant or intolerant Gastrointestinal Stromal Tumors (GIST) [2] - The combination therapy achieved a median progression-free survival (mPFS) of 16.5 months, significantly higher than the 9.2 months observed with sunitinib monotherapy [3] - The objective response rate (ORR) for the combination was 46%, compared to 26% for sunitinib alone [3] Group 2: Statistical Significance and Safety - The bezuclastinib combination demonstrated a 50% reduction in the risk of disease progression or death compared to the current standard of care, with highly statistically significant results [4] - The estimated mean duration of treatment for the bezuclastinib combination is projected to exceed 19 months, and the combination was generally well tolerated without unique risks compared to sunitinib [5] Group 3: Future Plans - Cogent plans to present detailed results from the Phase 3 PEAK trial at a major medical conference in the first half of 2026 and is on track to submit a new drug application (NDA) to the FDA for bezuclastinib in GIST during the same timeframe [6] Group 4: Stock Performance - As of the latest publication, Cogent Biosciences shares increased by 124.02%, reaching a price of $33.20, marking a new 52-week high [7]